CJC-1295 w/ DAC
Modified GRF(1-29) with DAC moiety for extended half-life research.
- Formula
- —
- CAS
- 863288-34-0
- Purity
- 99.0%
Lyophilized peptides supplied in sealed vials with batch documentation. All products are sold strictly for in-vitro research purposes.
Modified GRF(1-29) with DAC moiety for extended half-life research.
Modified GRF(1-29) without DAC moiety.
Dual-peptide research blend: CJC-1295 w/o DAC and Ipamorelin.
Copper tripeptide complex studied in dermal matrix and antioxidant research.
Copper tripeptide complex studied in dermal matrix and antioxidant research.
Tri-peptide research blend for combined dermal and recovery studies.
Higher-dose tri-peptide research blend.
Four-peptide research blend including KPV.
Triple agonist (GIP/GLP-1/glucagon) studied in metabolic models.
Triple agonist (GIP/GLP-1/glucagon) studied in metabolic models.
Triple agonist (GIP/GLP-1/glucagon) studied in metabolic models.
Triple agonist (GIP/GLP-1/glucagon) studied in metabolic models.
Triple agonist (GIP/GLP-1/glucagon) studied in metabolic models.
Triple agonist (GIP/GLP-1/glucagon) studied in metabolic models.
Long-arginine IGF-1 analog studied in growth-factor research.
Long-arginine IGF-1 analog studied in growth-factor research.
Selective GH-secretagogue pentapeptide.
Cyclic α-MSH analog studied in melanogenesis research.
Mitochondrial-derived peptide studied in metabolic homeostasis.
Mitochondrial-derived peptide studied in metabolic homeostasis.
Heptapeptide based on tuftsin, investigated in anxiolytic and nootropic models.
Heptapeptide based on tuftsin, investigated in anxiolytic and nootropic models.
Synthetic ACTH(4-10) analog studied for neurotrophic factor expression.
Synthetic ACTH(4-10) analog studied for neurotrophic factor expression.
Stabilized GHRH analog studied in visceral adipose research.
Stabilized GHRH analog studied in visceral adipose research.